Early Detection Research Network

Proteomics Biomarker Development Laboratory

Proteomics Biomarker Development Laboratory
53

No lead investigator defined.

No coordinating investigator defined.

No involved investigator sites defined.

No design specified.
UNKNOWN
[]

The Biomarker Development Laboratory is focused on the <br>application of a proteomic approach for the development<br> of cancer biomarkers. The laboratory will apply <br>technologies for protein analysis to the detection and <br>identification of proteins secreted by tumor cells and <br>protein antigens that induce a humoral response in tumor<br>s. The initial targeted tumor types for the identification<br> of potential biomarker proteins are: Colon, esophagus,<br> ovary, lung, breast and liver. The proposed studies will<br> make heavy utilization of two-dimensional (2-D) protein<br> analysis, of protein identification technologies and of <br>database capabilities that have been developed by the <br>applicant group. The objectives of this research are <br>to 1. Identify tumor antigens that induce a humoral <br>response; 2. Identify tumor secreted proteins and develop<br>a database; 3. Preliminarily validate the potential utility<br>of markers for early cancer detection. Sixty ml of blood<br>will be obtained from healthy normals, and from small <br>cell lung cancer, hepatoma, esophageal, and breast cancer<br>patients, and from ovarian, colon, and non-small cell lung<br>cancer patients prior to surgical resection and six to<br>ten weeks after resection. Demographic data, sera and <br>DNA will be used in 2-D protein analysis to identify new<br>or altered proteins. The initial validation will be the <br>assay of the presence or absence of a given protein in a<br>large sample cohort from the samples collected from these<br>patients. There is no specified age range, although the <br>diseases under study do not occur in children. No subjects<br>will be excluded on the basis of race or gender. Women<br>of child bearing age will be studied. Linkable demographic<br>data will be held separately from the bar-coded serum or<br>DNA samples. Serum and DNA sample will be identifiable<br>only by subject identification number. Full written <br>informed consent will be obtained from patients.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.